

Remarks

As indicated in the Office Action dated June 17, 2003, the subject application is in condition for allowance except for certain formal matters, and prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*.

The Office Action indicates that Figures 10 and 12 contain nucleotide or amino acid sequences that are not identified by SEQ ID NO.

The amino acid sequence shown in Figure 12 is found in SEQ ID NO. 21. Also, the AMV060 amino acid sequence shown in Figure 10 is found in SEQ ID NO. 16 (amino acid residues 1 to 295) and the AMV115 amino acid sequence shown in Figure 10 is found in SEQ ID NO. 17 (amino acid residues 1 to 292).

The substitute Sequence Listing further includes SEQ ID NOs. 75-80, which are consensus sequences within pox virus poly(a) polymerase subunit homologs in HaEPV (SEQ ID NO. 75); MSV041 (SEQ ID NO. 76); VVJ3R (SEQ ID NO. 77); consensus sequence between AMV060, AMV115, HaEPV, MSV041, and VVJ3R (SEQ ID NO. 78); insect consensus sequence (SEQ ID NO. 79); and consensus sequence between AMV060 and AMV115 of AmEPV (SEQ ID NO. 80), as shown in Figure 10 and as described in the Brief Description of the Drawings section at page 9, lines 13-16, of the specification.

By this Amendment, the applicants have added appropriate cross-references for the aforementioned sequences in the Brief Description of the Drawings section and Brief Description of the Sequences section of the specification.


In addition, the applicants have added three amino acids from Figure 10 as originally filed (AMV115 amino acid sequence) to SEQ ID NO. 17. The three amino acids are being added to SEQ ID NO. 17 at positions 59, 178, and 238. These amino acids were erroneously excluded from the Sequence Listing as filed.

Accordingly, upon entry of this Amendment, all sequences found in Figures 10 and 12 are identified by SEQ ID NOs. and present in the Sequence Listing pursuant to 37 C.F.R. §§1.821-1.825. A Submission of Sequence Listing and Statement under 37 C.F.R. §§1.821-1.825 is submitted herewith.

I hereby certify that no new material is being added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Glenn P. Ladwig
Patent Attorney
Registration No. 46,853
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachments: Submission of Sequence Listing and Statement under 37 C.F.R. §§1.821-1.825
Substitute Sequence Listing on paper and computer readable format
Copy of Notice to Comply with Requirements for Patent Applications containing
Nucleotide and/or Amino Acid Sequence Disclosures